Climacteric commentaries

References

• Alberti KG, Eckel RH, Grundy SM, et al Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–45.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis, and classification of diabetes mellitus and its complications. Part I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998;15:539–53
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 2005;366:1059–62
   PubMed Web of Science ®Google Scholar
• Bonow RO, Eckel RH. Diet, obesity, and cardiovascular risk. N Engl J Med 2003;348:2057–58
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008;121:149–57
   PubMed Web of Science ®Google Scholar
• Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome?Gynecol Endocrinol 1997;11:341–55
   PubMed Web of Science ®Google Scholar
• Stevenson JC. HRT and cardiovascular disease. In Lumsden MA, ed, Best Practice and Research Clinical Obstetrics and Gynaecology. Vol 23. New York: Elsevier, 2009:109–20.
   Google Scholar
• Woods LM, Rachet B, Lambert PC, Coleman MP. ‘Cure’ from breast cancer among two populations of women followed for 23 years after diagnosis. Ann Oncol 2009;20:1331–36
   PubMed Web of Science ®Google Scholar
• Francisci S, Capocaccia R, Grande E, et al The cure of cancer: a European perspective. Eur J Cancer 2009;45:1067–79
   PubMed Web of Science ®Google Scholar
• Verdecchia A, De Angelis R, Capocaccia R, et al The cure for colon cancer: results from the EUROCARE study. Int J Cancer 1998;77:322–9
   PubMed Web of Science ®Google Scholar
• Gamel JW, Meyer JS, Feuer E, Miller PA. The impact of stage and histology on the long-term clinical course of 163,808 patients with breast carcinoma. Cancer 1996;77:1459–64
   PubMed Web of Science ®Google Scholar
• Slade MJ, Singh A, Smith BM, et al Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. Int J Cancer 2005:114:94–100
   PubMed Web of Science ®Google Scholar
• Arslan AA, Shore RE, Afanasyeva Y, et al Circulating estrogen metabolites and risk for breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 2009;18:2273–9
   PubMed Web of Science ®Google Scholar
• Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270–82
   PubMed Web of Science ®Google Scholar
• Lippert TH, Seeger H, Mueck AO. Estrogens and the cardiovascular system: role of estradiol metabolites in hormone replacement therapy. Climacteric 1998;1:296–301
   PubMedGoogle Scholar
• Mueck AO, Seeger H, Lippert TH. Estradiol metabolism and malignant disease. Maturitas 2002;43:1–10
   PubMed Web of Science ®Google Scholar
• Seeger H, Wallwiener D, Krämer E, et al Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 2006;54:72–7
   PubMed Web of Science ®Google Scholar
• Osborne MP, Bradlow HL, Wong GY, et al Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst 1993;85:1917–20
   PubMed Web of Science ®Google Scholar
• Bradlow HL, Hershcopf RJ, Martucci CP, et al Estradiol 16alpha-hydroxylation in the mouse correlates with tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci USA 1985;82:6295–9
   PubMed Web of Science ®Google Scholar
• Seeger H, Zimmermann B, Brunner S, et al Estradiol metabolites in postmenopausal women with and without breast cancer – a case control study. Senologie 2008;5:211
   Google Scholar
• Mueck AO, Seeger H. Breast cancer: are estrogen metabolites carcinogenic? Climacteric 2007;10(Suppl 2):62–5
   PubMed Web of Science ®Google Scholar
• Cogliano V, Grosse Y, Baan R, et al WHO International Agency for Research on Cancer. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005;6:552–3
   PubMed Web of Science ®Google Scholar
• Schneider HP, Mueck AO, Kuhl H. IARC Monographs on carcinogenicity of combined hormonal contraceptives and menopausal therapy. Climacteric 2005;8:311–16
   PubMed Web of Science ®Google Scholar
• Esserman L, Shie Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685–92
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, et al ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–8
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL 3rd, et al Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–19
   PubMed Web of Science ®Google Scholar
• Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography [update of Cochrane Database Syst Rev 2001;(4):CD001877]. Cochrane Database Syst Rev 2006;(4): CD001877
   Web of Science ®Google Scholar
• Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009;339:b2587. doi: 10.1136/bmj.b2587
   PubMed Web of Science ®Google Scholar
• Cummings SR, Tice JA, Bauer S, et al Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 2009;101:384–98
   PubMed Web of Science ®Google Scholar
• http://www4.utsouthwestern.edu/breasthealth/cagene/.
   Google Scholar
• http://www.ems-trials.org/riskevaluator
   Google Scholar
• Kolios L, Hoerster A, Sehmisch S, et al Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis? Calcif Tissue Int 2009 Dec 1. Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Jackson RD, Wactawski-Wende J, LaCroix AZ, et al Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized trial. J Bone Miner Res 2006;21:817–28
   PubMed Web of Science ®Google Scholar
• Wells GA, Cranney A, Peterson J, et al Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1: CD001155
   Google Scholar
• Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009;122(2 Suppl):S33–45
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009;24:1095–102
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee D, Birkhauser MH, et al HRT in the early menopause: scientific evidence and common perceptions. Climacteric 2008;11:267–72
   PubMed Web of Science ®Google Scholar
• Davis SR, Hirschberg AL, Wagner LK, Lodhi I, von Schoultz B. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. J Clin Endocrinol Metab 2009;94:4907–13
   PubMed Web of Science ®Google Scholar
• Hofling M, Lundstrom E, Azavedo E, et al Testosterone addiction during menopausal hormone therapy: effects on mammographic breast density. Climacteric 2007;10:155–63
   PubMed Web of Science ®Google Scholar
• Birkhäuser H, Panay N, Archer DF, et al Updated practical recommendations for hormone replacement therapy in peri- and postmenopause. Climacteric 2008;11:108–23
   PubMed Web of Science ®Google Scholar
• Somboonporn W, Davis SR; National Health and Medical Research Council. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 2004;25:374–88
   PubMed Web of Science ®Google Scholar